Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12482627 | 0.92 | ALDH1A1 (0.53) | ALDH1A1ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL9538272 | 0.89 | ALDH1A1 (0.49) | ALDH1A1ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL12190874 | 0.87 | ALDH1A1 (0.61) | ALDH1A1ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL295187 | 0.86 | ALDH1A1 (0.56) | ALDH1A1ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL9463750 | 0.86 | ADRB2 (0.51) | ALDH1A1ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL9463824 | 0.84 | ADRB2 (0.52) | ALDH1A1ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL9463913 | 0.84 | PTPN1 (0.44) | ALDH1A1ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL9463533 | 0.84 | MAPT (0.41) | ALDH1A1ADRB2ADRB1ADRB3SLC1A5 | |
| SCHEMBL9463830 | 0.84 | GAA (0.46) | ALDH1A1ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL27933652 | 0.84 | ALDH1A1 (0.54) | ALDH1A1ADRB2ADRB1ADRB3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2128140-B1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-8030338-B2 | Method for producing 2-nitroimidazole derivative | POLA PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-8030338-B2 | Method for producing 2-nitroimidazole derivative | POLA PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-8030338-B2 | Method for producing 2-nitroimidazole derivative | POLA PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128140-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | Pola Pharma Inc. (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-5225590-A | Alkoxy methyl ether and alkoxy methyl ester derivatives | SYNTEX (U.S.A.) INC. (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0187297-B1 | ALKOXY METHYL ETHER AND ALKOXY METHYL ESTER DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1991-08-21 | — | — | EP | disclosed |
| EP-0187297-A2 | Alkoxy methyl ether and alkoxy methyl ester derivatives | SYNTEX (U.S.A.) INC. (US) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | GALK1, HOGA1, DERA | ALDH1A1 519/4885ADRB2 2232/4885ADRB1 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.